Corporate Banner
Satellite Banner
Biomolecular Screening
Scientific Community
 
Become a Member | Sign in
Home>News>This Article
  News
Return

Plexpress Expands Range of Pre-Validated Probes for ADME-Tox Studies

Published: Wednesday, August 29, 2012
Last Updated: Tuesday, August 28, 2012
Bookmark and Share
TRAC multiplexed gene expression analysis for increased throughput, efficiency and accuracy.

Plexpress has recently added to its growing library of pre-validated probes for multiplexed gene expression analysis. This includes many genes relevant for the investigation of in vitro drug interactions during pre-clinical studies, such as key members of the Cytochrome P450 family and many membranous transport channels.

Researchers can now select from hundreds of genes and carry out reliable, accurate and cost-effective ADME-Tox studies in a range of model systems, including human hepatocytes and rat liver tissue, with high sample throughput.

While the pre-validated panels are perfect for ‘off-the-shelf’ use, the TRAC system can also be set-up and optimized for any gene where the sequence is known, providing researchers with the flexibility to investigate any gene combination using both novel and pre-validated probes.

Jari Rautio, Ph.D., CEO of Plexpress, commented: “TRAC is ideal for ADME-Tox studies as it allows the rapid analysis of an investigational drug in many thousands of samples, without sacrificing the number of genes being analyzed. New compounds likely to be toxic or ineffective can therefore be identified early in the process, before costly clinical trials have taken place.”

The use of gene expression to analyze ADME-Tox profiles is widespread in drug discovery, a trend that is likely to continue given a recent draft from report from the FDA suggesting that drug discovery researchers use CYP mRNA induction, rather than CYP activity, to assess drug metabolism and activity.

Dr Rautio continued: “The TRAC approach has already proved very popular with Biotech, Pharma and Contract Research Organizations, as it offers significant accuracy, speed and cost benefits over more traditional targeted approaches such as qPCR. To-date TRAC been used by over 100 studies to investigate gene expression in a range of experimental systems.”

TRAC uses 96 well plates and avoids the need for RNA extraction, cDNA conversion and amplification, reducing experimental bias. It can also multiplex up to 30 genes per sample, providing expression profiles for all key genes in a single, fast experiment, while minimizing technical variation.

The Plexpress Human ADME-Tox panels can feature up to 6 reference genes and numerous targets including 14 CYP450 genes, glucuronosyl transferases, glutathione transferases and ABC transporters.

The Plexpress rat ADME-Tox library has over 14 reference genes and more than 120 targets to choose from including hepatotoxicity, necrosis, cholestasis and steatosis markers as well as those associated with drug metabolism and transport pathways.

Depending on the needs of each project, Plexpress can process user’s samples via its ISO9001 certified FAST TRAC gene expression service or assist with setting up TRAC in a user’s own laboratory.

TRAC is compatible with most third party magnetic bead processors and capillary electrophoresis devices.

Plexpress also offers a ‘one-stop-shop’ for studies requiring fully integrated gene discovery, validation and in-depth analysis.

The OneTRAC™ service, offered in collaboration with the Phalanx Biotech Group, combines the coverage breadth of Phalanx Biotech’s OneArray® microarrays with the high-throughput, multiplex capabilities of targeted TRAC analysis, allowing researchers to identify, select and validate a robust set of highly-relevant gene expression signatures.

As well as its application in biomarker development, the OneTRAC™ service is fully capable of addressing the diverse needs of academic research projects and drug discovery programs alike.


Further Information

Join For Free

Access to this exclusive content is for Technology Networks Premium members only.

Join Technology Networks Premium for free access to:

  • Exclusive articles
  • Presentations from international conferences
  • Over 3,000+ scientific posters on ePosters
  • More than 4,400+ scientific videos on LabTube
  • 35 community eNewsletters


Sign In



Forgotten your details? Click Here
If you are not a member you can join here

*Please note: By logging into TechnologyNetworks.com you agree to accept the use of cookies. To find out more about the cookies we use and how to delete them, see our privacy policy.

Related Content

Plexpress Announces Collaboration with Admescope
CRO to offer TRAC gene expression analysis for pre-clinical ADME-Tox studies.
Thursday, May 17, 2012
Plexpress Secures $2.3M to Commercialize TRAC High-Content Gene Expression Analysis Platform
Company targets applications including companion diagnostics and ADMET.
Thursday, April 19, 2012
Scientific News
Potential “Good Fat” Biomarker
New method to measure the activity of energy consuming brown fat cells could ease the testing weight loss drugs.
MicroRNA Pathway Could Lead to New Avenues for Leukemia Treatment
Cancer researchers at the University of Cincinnati have found a particular signaling route in microRNA (miR-22) that could lead to targets for acute myeloid leukemia, the most common type of fast-growing cancer of the blood and bone marrow.
Soy Shows Promise as Natural Anti-Microbial Agent
Soy isoflavones and peptides may inhibit the growth of microbial pathogens that cause food-borne illnesses, according to a new study from University of Guelph researchers.
Doubling Down on Dengue
HMS researchers have discovered two ways a compound blocks dengue virus.
Soy Shows Promise as Natural Anti-Microbial Agent
Researchers from University of Guelph show that soy isoflavones and peptides could be used to reduce microbial contamination of food.
AstraZeneca to Sequence 2 Million Genomes in Search for New Drugs
Company launches integrated genomics approach which aims to transform drug discovery and development.
Unique Model for Studying ALS
Unique mouse model will allow researchers to better study the genetic origins and potential treatments of ALS.
Targeting an ‘Undruggable’ Cancer Gene
RAS genes are mutated in more than 30 percent of human cancers and represent one of the most sought-after cancer targets for drug developers.
Biomarkers for Profiling Prostate Cancer Patients
Exiqon A/S has announced the publication of validation of prognostic microRNA biomarkers for the aggressiveness of prostate cancer in independent cohorts.
Improving Engineered T-Cell Cancer Treatment
Purdue University researchers may have figured out a way to call off a cancer cell assassin that sometimes goes rogue and assign it a larger tumor-specific "hit list."
SELECTBIO

SELECTBIO Market Reports
Go to LabTube
Go to eposters
 
Access to the latest scientific news
Exclusive articles
Upload and share your posters on ePosters
Latest presentations and webinars
View a library of 1,800+ scientific and medical posters
3,000+ scientific and medical posters
A library of 2,500+ scientific videos on LabTube
4,400+ scientific videos
Close
Premium CrownJOIN TECHNOLOGY NETWORKS PREMIUM FOR FREE!